23andMe leaders grilled on genetic data risks by federal lawmakers

23andMe's interim CEO disclosed to lawmakers that 1.9 million customers have requested data deletion since the company filed for bankruptcy in March, raising concerns about the future of its genetic database amid a court-supervised sale. Regeneron's initial $256 million acquisition bid is now subject to a reopened auction, while co-founder Anne Wojcicki is pursuing her own bid through a new nonprofit. The House Oversight Committee is examining privacy and national security risks associated with the sale of the DNA testing company.

Analysis

23andMe is navigating a critical phase following its March bankruptcy filing, characterized by a significant erosion of its core asset and heightened scrutiny over its sale. Interim CEO Joe Selsavage reported to federal lawmakers that 1.9 million of the company's 15 million DNA testing customers—approximately 12.7%—have requested data deletion since the bankruptcy, directly diminishing the value of its genetic database. This database is central to a court-supervised sale process marked by uncertainty; Regeneron Pharmaceuticals' initial $256 million acquisition offer has been subjected to a reopened auction, and co-founder Anne Wojcicki is pursuing a counter-bid through a new nonprofit, TTAM Research Institute. Further complicating the situation, the House Oversight Committee is examining the substantial privacy and national security risks associated with the company's sale, reflecting deep concerns over the handling of sensitive genetic information. These developments, coupled with a strongly negative sentiment surrounding 23andMe, underscore the severe challenges to its valuation and future prospects.

Key Decisions for Investors

• Investors holding 23andMe (ME) equity face substantial risk due to the ongoing bankruptcy proceedings, significant customer data deletion requests (1.9 million since March), and the uncertain outcome of the court-supervised sale.
• Potential acquirers, including Regeneron Pharmaceuticals and Anne Wojcicki's TTAM Research Institute, must critically assess the diminishing value of 23andMe's genetic database, evidenced by 12.7% of customers seeking data removal post-bankruptcy, alongside heightened privacy and national security scrutiny from lawmakers.
• This situation highlights the acute operational, reputational, and regulatory risks, particularly concerning data privacy and asset erosion, inherent in consumer-facing genetic data companies, especially those undergoing financial distress, warranting careful due diligence for any exposure in this sector.